Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benda’s Jiangling Plant Gets Production Approval

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22

You may also be interested in...



Lucrative Conference: Benda Recognizes $1.3 Million For Gendicine Order

SHANGAHI - Benda has recognized $1.3 million in revenues from an order worth $3.8 million placed at a recent conference for its cancer gene therapy Gendicine, the company announced Dec 5

Benda Anticipates 2008 Approval In India For Gene Therapy Product

SHANGHAI - China-Based Benda Pharmaceuticals anticipates 2008 approval from India's Central Drugs Control Organization for its gene therapy product Gendicine for treatment of head and neck cancer. The company filed its application for the recombinant human Ad-p53 injection in November

China's SFDA Sets New GMP Inspectional Guidelines

SHANGHAI - China's State Food and Drug Administration issued revised good manufacturing practice inspectional guidelines Oct. 24 in an effort to increase quality systems standards for pharmaceutical manufacturers. The new guidelines are scheduled to go into effect Jan. 1, replacing the current GMP inspectional guidelines, which were implemented in 1998

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel